Cargando…
Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study
BACKGROUND: Concurrent chemoradiation therapy (CCRT) followed by hepatic arterial infusional chemotherapy (HAIC) was reported to be effective for advanced hepatocellular carcinoma (HCC) with portal vein thrombosis. However, transarterial chemoembolization (TACE) is not preferred in this setting. The...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558652/ https://www.ncbi.nlm.nih.gov/pubmed/28810886 http://dx.doi.org/10.1186/s13014-017-0873-1 |
_version_ | 1783257418881302528 |
---|---|
author | Kim, Ja Kyung Kim, Jun Won Lee, Ik Jae Joo, Seung-Moon Lee, Kwang-Hun Cho, Eun-Suk Yu, Jeong-Sik Jeon, Tae Joo Kim, Yonsoo Lee, Jung Il Lee, Kwan Sik |
author_facet | Kim, Ja Kyung Kim, Jun Won Lee, Ik Jae Joo, Seung-Moon Lee, Kwang-Hun Cho, Eun-Suk Yu, Jeong-Sik Jeon, Tae Joo Kim, Yonsoo Lee, Jung Il Lee, Kwan Sik |
author_sort | Kim, Ja Kyung |
collection | PubMed |
description | BACKGROUND: Concurrent chemoradiation therapy (CCRT) followed by hepatic arterial infusional chemotherapy (HAIC) was reported to be effective for advanced hepatocellular carcinoma (HCC) with portal vein thrombosis. However, transarterial chemoembolization (TACE) is not preferred in this setting. The aim of this study was to assess the factors affecting survival after CCRT, including additional TACE during repeated HAIC. METHODS: Thirty-eight patients who underwent CCRT as the initial treatment for Barcelona Clinic Liver Cancer stage C HCC with vascular invasion between 2009 and 2016 were reviewed retrospectively. During CCRT, 5-fluorouracil (5-FU) was infused via chemoport during the first and last five days of five weeks of external beam radiation therapy. After CCRT, repeated HAIC with cisplatin and 5-FU was performed monthly. Nineteen patients (50%) underwent additional TACE between repeated HAICs. Factors related to overall survival and progression free survival (PFS) were analyzed. RESULTS: The mean age of patients was 55 years (male:female, 33:5). Underlying liver diseases were hepatitis B, hepatitis C and non-B/C in 29, 1 and 8 patients, respectively. The median radiation dose was 4500 cGy. The objective response (OR) rate at one months after CCRT was 36.8%. The median PFS was 7.4 (range, 1.8 − 32.1) months. The median overall survival was 11.6 (range 2.8-65.7) months. Achieving an OR after CCRT (hazard ratio [HR], 0.028; P < 0.001), additional TACE (HR, 0.134, P < 0.001), and further rounds of HAIC (HR, 0.742, P = 0.001) were independent significant factors related to overall survival. The overall survival duration of patients with an OR after CCRT (median 44.2 vs. 6.6 months, P < 0.001) and additional TACE (median 19.8 vs. 9.1 months, P = 0.001) were significantly greater than those without an OR after CCRT or additional TACE. CONCLUSION: Patients who achieved an OR after CCRT, underwent additional TACE, and were subjected to repeated rounds of HAIC following CCRT showed better survival after CCRT for advanced stage of HCC with vascular invasion. A further prospective study is needed to confirm the positive effect of additional TACE after CCRT. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13014-017-0873-1) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5558652 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-55586522017-08-16 Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study Kim, Ja Kyung Kim, Jun Won Lee, Ik Jae Joo, Seung-Moon Lee, Kwang-Hun Cho, Eun-Suk Yu, Jeong-Sik Jeon, Tae Joo Kim, Yonsoo Lee, Jung Il Lee, Kwan Sik Radiat Oncol Research BACKGROUND: Concurrent chemoradiation therapy (CCRT) followed by hepatic arterial infusional chemotherapy (HAIC) was reported to be effective for advanced hepatocellular carcinoma (HCC) with portal vein thrombosis. However, transarterial chemoembolization (TACE) is not preferred in this setting. The aim of this study was to assess the factors affecting survival after CCRT, including additional TACE during repeated HAIC. METHODS: Thirty-eight patients who underwent CCRT as the initial treatment for Barcelona Clinic Liver Cancer stage C HCC with vascular invasion between 2009 and 2016 were reviewed retrospectively. During CCRT, 5-fluorouracil (5-FU) was infused via chemoport during the first and last five days of five weeks of external beam radiation therapy. After CCRT, repeated HAIC with cisplatin and 5-FU was performed monthly. Nineteen patients (50%) underwent additional TACE between repeated HAICs. Factors related to overall survival and progression free survival (PFS) were analyzed. RESULTS: The mean age of patients was 55 years (male:female, 33:5). Underlying liver diseases were hepatitis B, hepatitis C and non-B/C in 29, 1 and 8 patients, respectively. The median radiation dose was 4500 cGy. The objective response (OR) rate at one months after CCRT was 36.8%. The median PFS was 7.4 (range, 1.8 − 32.1) months. The median overall survival was 11.6 (range 2.8-65.7) months. Achieving an OR after CCRT (hazard ratio [HR], 0.028; P < 0.001), additional TACE (HR, 0.134, P < 0.001), and further rounds of HAIC (HR, 0.742, P = 0.001) were independent significant factors related to overall survival. The overall survival duration of patients with an OR after CCRT (median 44.2 vs. 6.6 months, P < 0.001) and additional TACE (median 19.8 vs. 9.1 months, P = 0.001) were significantly greater than those without an OR after CCRT or additional TACE. CONCLUSION: Patients who achieved an OR after CCRT, underwent additional TACE, and were subjected to repeated rounds of HAIC following CCRT showed better survival after CCRT for advanced stage of HCC with vascular invasion. A further prospective study is needed to confirm the positive effect of additional TACE after CCRT. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13014-017-0873-1) contains supplementary material, which is available to authorized users. BioMed Central 2017-08-15 /pmc/articles/PMC5558652/ /pubmed/28810886 http://dx.doi.org/10.1186/s13014-017-0873-1 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Kim, Ja Kyung Kim, Jun Won Lee, Ik Jae Joo, Seung-Moon Lee, Kwang-Hun Cho, Eun-Suk Yu, Jeong-Sik Jeon, Tae Joo Kim, Yonsoo Lee, Jung Il Lee, Kwan Sik Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study |
title | Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study |
title_full | Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study |
title_fullStr | Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study |
title_full_unstemmed | Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study |
title_short | Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study |
title_sort | factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558652/ https://www.ncbi.nlm.nih.gov/pubmed/28810886 http://dx.doi.org/10.1186/s13014-017-0873-1 |
work_keys_str_mv | AT kimjakyung factorsaffectingsurvivalafterconcurrentchemoradiationtherapyforadvancedhepatocellularcarcinomaaretrospectivestudy AT kimjunwon factorsaffectingsurvivalafterconcurrentchemoradiationtherapyforadvancedhepatocellularcarcinomaaretrospectivestudy AT leeikjae factorsaffectingsurvivalafterconcurrentchemoradiationtherapyforadvancedhepatocellularcarcinomaaretrospectivestudy AT jooseungmoon factorsaffectingsurvivalafterconcurrentchemoradiationtherapyforadvancedhepatocellularcarcinomaaretrospectivestudy AT leekwanghun factorsaffectingsurvivalafterconcurrentchemoradiationtherapyforadvancedhepatocellularcarcinomaaretrospectivestudy AT choeunsuk factorsaffectingsurvivalafterconcurrentchemoradiationtherapyforadvancedhepatocellularcarcinomaaretrospectivestudy AT yujeongsik factorsaffectingsurvivalafterconcurrentchemoradiationtherapyforadvancedhepatocellularcarcinomaaretrospectivestudy AT jeontaejoo factorsaffectingsurvivalafterconcurrentchemoradiationtherapyforadvancedhepatocellularcarcinomaaretrospectivestudy AT kimyonsoo factorsaffectingsurvivalafterconcurrentchemoradiationtherapyforadvancedhepatocellularcarcinomaaretrospectivestudy AT leejungil factorsaffectingsurvivalafterconcurrentchemoradiationtherapyforadvancedhepatocellularcarcinomaaretrospectivestudy AT leekwansik factorsaffectingsurvivalafterconcurrentchemoradiationtherapyforadvancedhepatocellularcarcinomaaretrospectivestudy |